STOCK TITAN
  1. Home
  2. News
  3. BIIB

Biogen Inc - BIIB STOCK NEWS

Welcome to our dedicated news page for Biogen (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biogen's position in the market.

News
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
Rhea-AI Summary
Biogen Inc. (Nasdaq: BIIB) receives a positive recommendation from the CHMP for SKYCLARYS® (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in people aged 16 years and older in the European Union, marking a significant milestone in the company's focus on rare diseases and addressing unmet patient needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none
-
News
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
Rhea-AI Summary
Biogen Inc. (BIIB) and Sage Therapeutics, Inc. (SAGE) have announced the availability of ZURZUVAE™ (zuranolone) 50 mg for the treatment of postpartum depression (PPD) in the United States. ZURZUVAE is the first and only oral, 14-day treatment course for adults with PPD that can provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3. The product is already at specialty pharmacies and delivered to patients. ZURZUVAE has the potential to make a profound difference in the lives of women with PPD, according to Dr. Kristina Deligiannidis, a principal investigator in the ZURZUVAE clinical development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
News
Biogen Appoints Monish Patolawala to its Board of Directors
Rhea-AI Summary
Biogen Inc. has announced the appointment of Monish Patolawala, the current President and CFO of 3M Company, to its Board of Directors, effective January 1, 2024. Patolawala brings over 25 years of experience in leading financial operations and businesses in the industrial and healthcare sectors. His expertise will be valuable as Biogen focuses on operational execution to achieve its financial goals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
management
News
EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
Rhea-AI Summary
Eisai and Biogen present new data for LEQEMBI at the Clinical Trials on Alzheimer's Disease conference. Subcutaneous formulation shows better plaque removal and higher pharmacokinetics compared to IV. 76% of patients in the low-tau subpopulation showed no decline and 60% showed clinical improvement at 18 months. LEQEMBI supports brain neuron function by removing toxic proteins.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
clinical trial
-
News
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
Rhea-AI Summary
Biogen reports positive Phase 1b clinical data for BIIB080 in mild Alzheimer's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
-
News
LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023
Rhea-AI Summary
Eisai Inc. and Biogen Inc.'s LEQEMBI selected as one of the Best Inventions of 2023 by TIME in the Medical Care category. LEQEMBI is the first approved treatment for Alzheimer's disease. The treatment can cause amyloid related imaging abnormalities (ARIA) and is contraindicated in patients with hypersensitivity to lecanemab-irmb.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
News
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
Rhea-AI Summary
Biogen to present new data on Alzheimer's disease portfolio at upcoming CTAD meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences clinical trial
-
News
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
Rhea-AI Summary
Biogen's TOFIDENCE (BIIB800) receives FDA approval as the first tocilizumab biosimilar in the US, expanding access to therapies for autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
-
News
Biogen Completes Acquisition of Reata Pharmaceuticals
Rhea-AI Summary
Biogen completes acquisition of Reata Pharmaceuticals, adding SKYCLARYS® to its rare disease portfolio. SKYCLARYS® is the first FDA approved treatment for Friedreich’s ataxia. Commercial launch underway in the US. European regulatory review ongoing. Over 1,000 patient start forms submitted in the US. Anticipates significant synergies with existing rare disease portfolio. Acquisition expected to be slightly dilutive to Non-GAAP EPS in 2023, neutral in 2024, and significantly accretive beginning in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
acquisition
News
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
Rhea-AI Summary
Eisai and Biogen announce approval of LEQEMBI in Japan for the treatment of Alzheimer's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
Stock BIIB logo
Biogen Inc

Nasdaq:BIIB

BIIB Rankings

#398 Ranked by Market Cap
#3170 Ranked by Stock Gains
N/A Ranked by Dividends

BIIB Stock Data

28.37B
144.82M
0.69%
92.98%
2.44%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About BIIB

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili